CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Revlimid (in combo) bortezomib + dexamethasone for newly diagnosed Multiple Myeloma – Details

Project Number PC0141-000
Brand Name Revlimid
Generic Name Lenalidomide
Strength 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg
Tumour Type Myeloma
Indication Multiple Myeloma
Funding Request The combination of lenalidomide, bortezomib, and low-dose dexamethasone, for the treatment of newly diagnosed multiple myeloma patients in whom stem cell transplantation is not intended
Review Status Complete
Pre Noc Submission No
NOC Date N/A
Manufacturer Celgene Inc.
Sponsor Celgene Inc.
Submission Date (Target Date) December 21, 2018
Submission Deemed Complete January 14, 2019
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline ‡ January 14, 2019
Check-point meeting March 5, 2019
pERC Meeting May 16, 2019
Initial Recommendation Issued May 31, 2019
Feedback Deadline ‡ June 14, 2019
Final Recommendation Issued June 19, 2019
Notification to Implement Issued July 5, 2019
Therapeutic Area Multiple Myeloma (+bortezomib+dex)
Recommendation Type Do not reimburse

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.